Patient characteristics
| . | Recipients (n = 15) . |
|---|---|
| Enrollment period | January 2013 to March 2014 |
| Age, median (range), y | 52 (27-68) |
| Sex | |
| Male | 11 (73.3) |
| Female | 4 (26.7) |
| Disease | |
| AML | 6 (40) |
| ALL | 4 (26.7) |
| MDS | 1 (6.7) |
| LPD | 3 (20) |
| PCM | 1 (6.7) |
| Donor source | |
| Unrelated PBSCs | 15 (100) |
| Conditioning | |
| Cy/TBI | 3 (20) |
| Flu/Mel | 12 (80) |
| CMV status | |
| R+/D+ | 6 (40) |
| R+/D− | 5 (33.3) |
| R−/D+ | 2 (13.3) |
| R−/D− | 2 (13.3) |
| . | Recipients (n = 15) . |
|---|---|
| Enrollment period | January 2013 to March 2014 |
| Age, median (range), y | 52 (27-68) |
| Sex | |
| Male | 11 (73.3) |
| Female | 4 (26.7) |
| Disease | |
| AML | 6 (40) |
| ALL | 4 (26.7) |
| MDS | 1 (6.7) |
| LPD | 3 (20) |
| PCM | 1 (6.7) |
| Donor source | |
| Unrelated PBSCs | 15 (100) |
| Conditioning | |
| Cy/TBI | 3 (20) |
| Flu/Mel | 12 (80) |
| CMV status | |
| R+/D+ | 6 (40) |
| R+/D− | 5 (33.3) |
| R−/D+ | 2 (13.3) |
| R−/D− | 2 (13.3) |
Values are presented as n (%) of patients unless otherwise indicated.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; Cy, cyclophosphamide; D, donor; Flu, fludarabine; LPD, lymphoproliferative disorder (chronic lymphocytic leukemia, Hodgkin disease, non-Hodgkin lymphoma); MDS, myelodysplastic syndrome; Mel, melphalan; PBSC, peripheral blood stem cells; PCM, plasma cell myeloma; R, recipient; TBI, total body irradiation.